OncoGenex files $60 million shelf covering stock, debt and preferreds

By Devika Patel

Knoxville, Tenn., Nov. 3 - OncoGenex Pharmaceuticals, Inc. filed a $60 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock, debt securities and warrants.

The securities may be structured as convertibles.

Proceeds will be used for general corporate purposes.

OncoGenex Pharmaceuticals, based in Bothell, Wash., is a biopharmaceutical company engaged in the development and commercialization of cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.